SPARC.NS Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 12:00):

Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally...

Stats
Tagesvolumen	592 026
Durchschnittsvolumen	515 848
Marktkapitalisierung	83.52B
EPS	INR0 ( 2024-02-04 )
Nächstes Ertragsdatum	( INR0 ) 2024-05-19
Last Dividend	INR0 ( N/A )
Next Dividend	INR0 ( N/A )
P/E	-22.73
ATR14	INR0 (0.00%)

Volumen Korrelation

Lang: 0.00 (neutral)

Kurz: 0.00 (neutral)

Signal:(0) Neutral

Sun Pharma Advanced Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Sun Pharma Advanced Korrelation - Währung/Rohstoff

0.00
( neutral )

Sun Pharma Advanced Finanzdaten

Annual	2022
Umsatz:	INR2.31B
Bruttogewinn:	INR592.00M (25.65 %)
EPS:	INR-7.82

FY	2022
Umsatz:	INR2.31B
Bruttogewinn:	INR592.00M (25.65 %)
EPS:	INR-7.82

FY	2022
Umsatz:	INR1.37B
Bruttogewinn:	INR105.52M (7.69 %)
EPS:	INR-8.24

FY	2021
Umsatz:	INR2.53B
Bruttogewinn:	INR465.55M (18.40 %)
EPS:	INR-5.77

Financial Reports:

No articles found.

Sun Pharma Advanced

Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities, and reformulated products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, and dermatology. The company offers Elepsia, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; and Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; phenobarbital sodium for the treatment of neonatal seizures; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet SCR to develop an S1P receptor 1 agonist for autoimmune disorders; and HitGen Ltd. to identify small molecule leads for targets of interest. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Private Limited